Welcome to our dedicated page for Vaxart SEC filings (Ticker: VXRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxart, Inc. filings document a clinical-stage biotechnology issuer focused on oral recombinant pill vaccines and a common stock quoted on the OTCQX Best Market under the symbol VXRT. The company’s regulatory record includes financial-result 8-K reports, registration statements and registration-rights disclosures tied to common stock financing, and exhibits covering material agreements.
The filings also cover board appointments and independence determinations, lease terminations and facility changes, capital structure items, revenue categories such as government contract and collaboration revenue, and formal market-status records, including a Form 25 for removal of the common stock from Nasdaq listing and registration.
Vaxart, Inc. entered into a new modification of its BARDA-funded Project NextGen contract, resetting total funding for its Phase 2b oral COVID‑19 pill vaccine trial to approximately $345 million, which is about $116 million lower than the prior modification after trial enrollment was cut roughly in half by a BARDA partial termination.
The revised amount includes about $68 million of firm fixed price funding, with the remainder reimbursing trial preparation and execution costs, and also releases roughly $29 million to complete the study and perform exploratory safety and efficacy analyses. Vaxart expects to report 12‑month data from a 400‑participant sentinel cohort in the coming weeks and from the 5,085‑participant main cohort in the first half of 2027.
Vaxart, Inc. faces a shareholder-led proxy contest: a coalition calling itself the Concerned Vaxart Stockholders, owning 1,515,343 shares, filed a definitive proxy statement and universal proxy card seeking to elect three nominees to the Board at the 2026 annual meeting.
The group asks for greater transparency, accountability, and Board-level reforms including a Clinical and Regulatory Affairs Committee and a Stockholder Relations Committee, and outlines strategic partnership ideas while emphasizing constructive engagement rather than disruption.
Concerned Vaxart Stockholders, a retail coalition holding 1,515,343 shares, filed a definitive proxy and a GOLD universal proxy card to elect three nominees — Daniel P. Houle, Mark Silverberg, DDS, MD, and Matthew M. Wallace, MD — to Vaxart’s board at the July 16, 2026 annual meeting. The group cites a 91% decline in the share price, approximately $343 million in cumulative losses since 2020, executive compensation of $5.2 million for fiscal 2025, issuance of 50 million new shares on June 13, 2024, and prior governance disputes including a rejected reverse stock split vote and disclosure concerns regarding a former director.
Vaxart, Inc. is soliciting proxies for its 2026 virtual Annual Meeting and is asking stockholders to vote FOR its six director nominees on the enclosed WHITE proxy card. The Board states that a stockholder, Daniel P. Houle, intends to nominate three opposing candidates and urges holders to discard any [•] proxy cards received from Mr. Houle.
The filing recounts prior engagement with Mr. Houle and other stockholders dating to August 2025, describes the Board’s candidate selection and recent appointment of James B. Breitmeyer, M.D., Ph.D., and summarizes prior governance actions including two reverse-split proposals in 2025, Nasdaq delisting actions, and related shareholder solicitations.
Vaxart, Inc. director Watson W. Mark reported an open-market purchase of 10,000 shares of Common Stock on May 22, 2026 at $0.653 per share. Following this transaction, he directly holds 134,125 shares of Vaxart common stock.
Vaxart proxy contest: A group led by Daniel P. Houle and five other participants is soliciting proxies to elect three nominees to Vaxart's six-member Board at the 2026 Annual Meeting, citing underperformance and governance concerns. The group reports beneficial ownership of 1,515,343 shares and will use a GOLD universal proxy card to solicit votes for a six-member slate.
The proxy statement details the nominees, voting mechanics for the virtual meeting, potential change-of-control effects under several equity and severance plans, and transaction schedules for the participants.
Vaxart, Inc. Chief Financial Officer Jeroen Nicolaas Grasman reported a tax-related share disposition connected to vested restricted stock units. On May 19, 2026, 31,395 shares of common stock were withheld by the company at $0.61 per share to satisfy income tax withholding and remittance obligations. This was a non-market transaction used to settle taxes rather than an open-market sale. After this withholding, Grasman directly held 545,605 shares of Vaxart common stock.
Vaxart, Inc. filed a preliminary proxy statement for its 2026 virtual Annual Meeting describing a contested director election: a stockholder, Daniel P. Houle, intends to nominate three director candidates in opposition to the Board’s slate. The Board unanimously recommends voting FOR its six nominees on the enclosed WHITE proxy card.
The filing discloses prior engagement with Mr. Houle and related investors, including that the Houle group collectively beneficially owned 1,739,782 shares (about 0.7%) as of February 20, 2026, and that Mr. Houle personally held 15,622 shares (less than 0.007%). The proxy recounts 2025 events including two reverse-split proposals, Nasdaq delisting and trading on OTCQX, the Board’s refreshment (appointment of Dr. James B. Breitmeyer on April 23, 2026), and governance and voting procedures under the universal proxy rules.